Sanofi Press Releases

SNY 
$47.15
*  
0.58
1.25%
Get SNY Alerts
*Delayed - data as of Nov. 21, 2014  -  Find a broker to begin trading SNY now
Exchange: NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By
European CHMP Adopts Positive Opinion for Genzyme’s Cerdelga® (eliglustat) Capsules
11/21/2014 7:15:00 AM - Business Wire


Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis
11/20/2014 1:30:00 AM - PR Newswire


Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
11/19/2014 8:15:00 AM - PR Newswire


Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
11/19/2014 8:15:00 AM - PR Newswire


Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
11/18/2014 3:45:00 PM - Business Wire


Sanofi Names Chief Scientific Officer Gary Nabel as Sanofi Ebola Response Coordinator
11/18/2014 11:22:00 AM - PR Newswire


Genzyme’s Lemtrada Approved by the FDA
11/14/2014 9:00:00 PM - Business Wire


Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
11/11/2014 1:00:00 AM - PR Newswire


Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma
11/11/2014 1:00:00 AM - PR Newswire


Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis
11/4/2014 6:00:00 AM - Business Wire
▲3.60 % Price Change since this news event. The Volume Ratio is 0.23.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sanofi Pasteur Announces FDA Approval of Updated Prescribing Information for Fluzone® High-Dose Vaccine for Adults 65 and Older
11/3/2014 8:30:00 AM - PR Newswire
▲3.90 % Price Change since this news event. The Volume Ratio is 0.48.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sanofi: Sanofi Delivers Business EPS Growth of 10.3% at CER
10/28/2014 8:34:00 AM - PR Newswire
▼-2.48 % Price Change since this news event. The Volume Ratio is 5.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


New International GPCR Consortium Formed with Pharma and Academia to Advance Structural Information about G-protein Coupled Receptors
10/28/2014 6:00:00 AM - PR Newswire
▼-2.72 % Price Change since this news event. The Volume Ratio is 5.86.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Sanofi Q3 2014 Results - Interview with Jérôme Contamine
10/28/2014 3:00:00 AM - PR Newswire
▼-10.87 % Price Change since this news event. The Volume Ratio is 5.4.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
10/20/2014 10:35:00 AM - Business Wire
▼-8.25 % Price Change since this news event. The Volume Ratio is 0.3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine
10/20/2014 8:00:00 AM - Business Wire


Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis
10/20/2014 7:00:00 AM - PR Newswire


Amgen Files Lawsuit Against Sanofi And Regeneron For Patent Infringement
10/17/2014 9:00:00 AM - PR Newswire


Farmland Partners Inc. Announces Agreements for Acquisition of $25 Million of Farms and Increase of the Farmer Mac Facility to $75 Million
10/17/2014 9:00:00 AM - PR Newswire


Sanofi Pasteur and Immune Design Enter Broad Collaboration for the Development of a Herpes Simplex Virus Therapy
10/16/2014 8:00:00 AM - GlobeNewswire


New Survey Finds Differences In Attitudes About Diabetes Based On Age
10/15/2014 8:00:00 AM - PR Newswire
▼-9.48 % Price Change since this news event. The Volume Ratio is 1.61.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Unilife Signs 15-Year Commercial Supply Agreement for Wearable Injectors with Sanofi
10/6/2014 8:00:00 AM - PR Newswire


Genzyme Announces Winners of Patient Advocacy Leadership (PAL) Awards
10/1/2014 8:00:00 AM - Business Wire


Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps
9/30/2014 1:00:00 AM - PR Newswire


Genzyme Collaborates on Gene Therapy for Rare Disease that Causes Childhood Blindness
9/24/2014 8:00:00 AM - Business Wire